Radojka M Savic1, Daniël M Jonker, Thomas Kerbusch, Mats O Karlsson. 1. Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Uppsala 75234, Sweden. Rada.Savic@farmbio.uu.se
Abstract
PURPOSE: To compare the performance of the standard lag time model (LAG model) with the performance of an analytical solution of the transit compartment model (TRANSIT model) in the evaluation of four pharmacokinetic studies with four different compounds. METHODS: The population pharmacokinetic analyses were performed using NONMEM on concentration-time data of glibenclamide, furosemide, amiloride, and moxonidine. In the TRANSIT model, the optimal number of transit compartments was estimated from the data. This was based on an analytical solution for the change in drug concentration arising from a series of transit compartments with the same first-order transfer rate between each compartment. Goodness-of-fit was assessed by the decrease in objective function value (OFV) and by inspection of diagnostic graphs. RESULTS: With the TRANSIT model, the OFV was significantly lower and the goodness-of-fit was markedly improved in the absorption phase compared with the LAG model for all drugs. The parameter estimates related to the absorption differed between the two models while the estimates of the pharmacokinetic disposition parameters were similar. CONCLUSION: Based on these results, the TRANSIT model is an attractive alternative for modeling drug absorption delay, especially when a LAG model poorly describes the drug absorption phase or is numerically unstable.
PURPOSE: To compare the performance of the standard lag time model (LAG model) with the performance of an analytical solution of the transit compartment model (TRANSIT model) in the evaluation of four pharmacokinetic studies with four different compounds. METHODS: The population pharmacokinetic analyses were performed using NONMEM on concentration-time data of glibenclamide, furosemide, amiloride, and moxonidine. In the TRANSIT model, the optimal number of transit compartments was estimated from the data. This was based on an analytical solution for the change in drug concentration arising from a series of transit compartments with the same first-order transfer rate between each compartment. Goodness-of-fit was assessed by the decrease in objective function value (OFV) and by inspection of diagnostic graphs. RESULTS: With the TRANSIT model, the OFV was significantly lower and the goodness-of-fit was markedly improved in the absorption phase compared with the LAG model for all drugs. The parameter estimates related to the absorption differed between the two models while the estimates of the pharmacokinetic disposition parameters were similar. CONCLUSION: Based on these results, the TRANSIT model is an attractive alternative for modeling drug absorption delay, especially when a LAG model poorly describes the drug absorption phase or is numerically unstable.
Authors: Hanna E Silber; Claudia Burgener; Ingrid M Letellier; Mathieu Peyrou; Martin Jung; Jonathan N King; Philippe Gruet; Jerome M Giraudel Journal: Pharm Res Date: 2010-10-05 Impact factor: 4.200
Authors: Elin Svensson; Jan-Stefan van der Walt; Karen I Barnes; Karen Cohen; Tamara Kredo; Alwin Huitema; Jean B Nachega; Mats O Karlsson; Paolo Denti Journal: Br J Clin Pharmacol Date: 2012-09 Impact factor: 4.335
Authors: R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré Journal: Clin Pharmacol Ther Date: 2012-10-03 Impact factor: 6.875
Authors: Nieves Vélez de Mendizábal; Alexander Staab; Hans Günter Schäfer; Dirk Trommeshauser; Christiane Döge; Matthias Klüglich; Juliet Roberts; Iñaki F Trocóniz Journal: Pharm Res Date: 2012-12-11 Impact factor: 4.200